Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab immune microenvironment study in postmenopausal HER2-negative breast cancer
NL-OMON46766Phase 2Withdrawn
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denosumab in breast cancer (3 arms), sponsored by Borstkanker Onderzoek Groep. Planned start Dec 2017; status: withdrawn.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON46766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46766.